Skip to main content

Table 1 Clinical and laboratory characteristics

From: Posterior reversible encephalopathy syndrome could be an underestimated variant of “reversible neurological deficits” in Systemic Lupus Erythematosus

  10 episodes, no. (%)
Demographics  
Age at onset (years) 22.93 ± 2.48 *
Female 10 (100)
SLE characteristics  
Duration (months) 20.8 ± 12.8*
Fever 8 (80)
Rash 8 (80)
Photosensitive 6 (60)
Ulcers 5 (50)
Arthritis/arthralgia 10 (100)
Serositis 5 (50)
Lymphadenopathy 5 (50)
Vasculitis 4 (40)
Reynaud’s phenomena 4 (40)
SLEDAI 25.8 ± 5.7*
Associated risk factors  
Acute hypertension 8 (80)
<160/100 mmHg 5 (50)
≥170/110 mmHg 3 (30)
Renal failure (cr. ≥1.5 mg/dl) b 2 (20)
Neurological manifestations  
Seizures 8 (80)
Coma 6 (60)
Headache 3 (30)
Vomiting 3 (30)
Cortical blindness 2 (20)
Stupor 1(10)
Laboratory findings  
Leucopenia 6 (60)
Lymphopenia 2 (20)
Anemia 5 (50)
Thrombocytopenia 3 (30)
Proteinuria 8 (80)
Hypoproteinemia 8 (80)
Hypocomplementemia 8 (80)
Anti-SSA 7 (70)
Anti-SSB 2 (20)
Anti-dsDNA 6 (60)
Anti-RNP/Sm 3 (30)
Anti- Sm 2 (20)
Anti-Nucleosomes 2 (20)
aPL 4 (40)
Treatmentb  
Methylprednisolone pulses 8 (80)
Cyclophosphamide 8 (80)
Outcome  
Complete neurological recovery 8 (80)
Residual neurological deficit 1(10)
Death 1(10)
  1. SLEDAI: Systemic Lupus Erythematosus Disease Activity Index [23] aPL: antiphospholipid antibodies. Mean and S.D.
  2. b.At clinical onset.